Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.69 |
| ▸ | MET | P08581 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 13/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 2/20 | 0.51 |
| ▸ | YES1 | P07947 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412261 | 0.91 | MET (0.68) | AURKAAURKBMETSRCPDGFRB | |
| SCHEMBL5417536 | 0.89 | MET (0.61) | AURKAAURKBMETSRCPDGFRB | |
| SCHEMBL5402667 | 0.87 | MET (0.63) | AURKAAURKBMETSRCPDGFRB | |
| SCHEMBL6389508 | 0.83 | SRC (0.64) | AURKASRCPDGFRBFGFR1LCK | |
| SCHEMBL6389502 | 0.83 | SRC (0.64) | AURKASRCPDGFRBFGFR1LCK | |
| SCHEMBL3797737 | 0.83 | AURKA (0.72) | AURKAAURKBMETSRCPDGFRB | |
| SCHEMBL3797740 | 0.83 | AURKA (0.72) | AURKAAURKBMETSRCPDGFRB | |
| SCHEMBL5419723 | 0.83 | MET (0.57) | AURKAAURKBMETSRCPDGFRB | |
| SCHEMBL6408977 | 0.82 | SRC (0.75) | AURKASRCPDGFRBFGFR1LCK | |
| SCHEMBL6408973 | 0.82 | SRC (0.75) | AURKASRCPDGFRBFGFR1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | AURKA 463/4885AURKB 414/4885MET 2590/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | AURKA 78/4885AURKB 125/4885MET 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.